This international clinical trial aims to identify treatments that may be beneficial for people hospitalised with suspected or confirmed COVID-19
A range of potential treatments have been suggested for COVID-19 but nobody knows if any of them will turn out to be more effective in helping people recover than the usual standard of hospital care which all patients will receive. The RECOVERY Trial is currently testing some of these suggested treatments:
- baricitinib (an immunomodulatory drug used in rheumatoid arthritis)
- dimethyl fumarate (an immunomodulatory drug used in psoriasis and multiple sclerosis)
- high-dose vs standard corticosteroids.
Data from the trial are regularly reviewed so that any effective treatment can be identified quickly and made available to all patients. Please see our news page for results that RECOVERY has already found. The RECOVERY Trial team will constantly review information on new drugs and include promising ones in the trial.
Letters from the Chief Medical Officers
The Chief Medical Officers of England, Wales, Scotland and Northern Ireland, and the NHS Medical Director, have written to all doctors strongly encouraging participation in the national randomised trials in COVID-19 of which RECOVERY is one. You can read the letters by following the links below. Please pass them on to your colleagues.
The importance of increasing recruitment
The importance of COVID-19 clinical trials
Recruiting patients for clinical trials for Covid-19 therapeutics
The RECOVERY Trial is registered at ISRCTN50189673
EU Clinical Trials Register: EudraCT 2020-001113-21
Clinical Trials.gov: NCT04381936
Navigating this site
All study documents, including the Participant Information Sheet and Consent form, and those required by R&D departments and pharmacists, can be downloaded from the For Site Staff area of the site.
The Randomisation Program for sites that will take part in the trial post-training, and all relevant documents can be accessed on the Randomisation page.
The study protocol can be freely downloaded here.
FUNDERS
This trial is supported by grants to the University of Oxford from the National Institute for Health Research (NIHR), UK Research and Innovation, and Wellcome, and by core funding provided by the Bill and Melinda Gates Foundation, the Foreign, Commonwealth & Development Office, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Oxford Biomedical Research Centre, NIHR Clinical Trials Unit Support Funding, and Wellcome.